Bristol-Myers Squibb (BMY)

We may still be in the early innings of the AI revolution, and these companies could be among the biggest winners.

As investors rotate toward value, Altria, Bristol Myers Squibb, and American Electric Power stand out as reliable dividend stocks with strong payout growth histories and defensive appeal.

Analysts aren't nearly as bullish about Bristol Myers Squibb as this billionaire hedge fund manager is.

Sometimes you need to look beyond the numbers to get the full story.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Could it become as successful in this niche as it was in the coronavirus vaccine market?

Drug pricing matters, but pipelines matter even more.

They may not remain cheap for too much longer.

It doesn't get much more dependable and lucrative than the healthcare industry.

This big pharma stock looks attractive for income investors -- but it comes with some risk.

Strong productivity gains from AI -- and lower inflation -- could be good news for these Vanguard ETFs.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?

Learn how a vertical spread options strategy can help reduce risk, lock in gains, and stay invested in winning trades.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.

Fears about a looming patent cliff have dragged on the shares.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

They have a habit of consistently raising their payouts.

Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe.

"Productivity initiatives" could prove key in maintaining this pharma company's decades-long dividend growth streak.

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

What does this smart money investor see that the market is missing?